Skip to main content

Table 2 Subject characteristics at baseline

From: Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Baseline demographics

Total (N = 30)

Age – Mean (SD), years

60.5 (6.6)

Age – Range, years

40–70

Female, n (%)

6 (20.0)

Male, n (%)

24 (80.0)

Active smoker, n (%)

17 (56.7)

Former smoker, n (%)

13 (43.3)

Number of pack-years – Mean (SD), years

42.9 (16.40)

Number of pack-years – Range, years

14–88

Parameter

Pre-bronchodilator

Post-bronchodilatora

FEV1 – Mean (SD), L

1.48 (0.48)

1.73 (0.41)

Pre-bronchodilator FVC – Mean (SD), L

3.27 (0.68)

3.72 (0.73)

Percent predicted FEV1 – Mean (SD), %

51.4 (15.08)

56.8 (12.96)

FEV1/FVC – Mean (SD), %

49.8 (11.12)

51.9 (12.16)

  1. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, SD standard deviation
  2. aFollowing inhalation of ipratropium bromide